JW Pharmaceutical's JW1601 begins Phase 2 clinical trials

JW1601, an oral atopy treatment candidate that was licensed by JW Pharmaceutical to Ballerup, Denmark-based Leo Pharma began Phase 2 clinical trials, the Korean company said Wednesday.